https://www.selleckchem.com/pr....oducts/lanraplenib.h
19-6.77), malignancy (pOR 2.38, 95% CI 1.25-4.52), diabetes (pOR 2.29, 95% CI 1.56-3.39), hypertension (pOR 1.72, 95% CI 1.23-2.42), cardiovascular disease (pOR 1.61, 95% CI 1.31-1.98) and chronic kidney disease (pOR 1.46, 95% CI 1.06-2.02), for predicting severe COVID-19. Our analysis describes the association of specific symptoms and comorbidities with severe COVID-19 disease. Knowledge of these clinical determinants will assist the clinicians in the risk-stratification of these patients for better triage and clinical management.
Like
Comment
Share
